Skip to main content
Equibles

Prakhar Agarwal

Analyst

Cantor Fitzgerald

Equibles does not estimate personal net worth.

About Prakhar Agarwal

Prakhar Agarwal is recorded as Analyst at Cantor Fitzgerald. Prakhar Agarwal has spoken on 2 investor events across 2 companies, most recently for Travere Therapeutics, Inc. on April 13, 2026. Those appearances were for Travere Therapeutics, Inc. (TVTX) and aTYR PHARMA INC (ATYR). The companies whose calls Prakhar Agarwal spoke on are classified in the Healthcare sector.

Prakhar Agarwal on recent calls

“Well, maybe just firstly, you mentioned less than 20% have active nephrotic syndrome. Could you clarify if that's relevant for secondary FSGS as well? And what could be the uptake B in primary versus secondary FSGS, given secondary population was not included in duplex, but a much larger segment overall?”
Analyst — Cantor Fitzgerald, Travere Therapeutics FDA Approval of FILSPARI in FSGS Conference Call ·
“Maybe a couple on pulmonary sarcoidosis. How did the ability to taper even beyond the 12-week tapering protocol impact the trial results on the placebo on performance?”
Analyst — Cantor Fitzgerald, aTyr Pharma Conference Call ·

Affiliation history

  • Cantor Fitzgerald

    Analyst

    Transcript header (unverified)

    Current

Company network

Recent activity